Amgen Inc. faced a notable decline in its stock price as broader market conditions favored other sectors.
Amgen Inc. (NASDAQ:AMGN) experienced a downturn yesterday, closing at CA$407.27, down 3.38%. This decline occurred while the overall market showed modest gains, highlighting Amgen's challenges in a competitive biotech landscape.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$227.88B
P/E
26.3x
Div. yield
2.31%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+0.30%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 30, 2026
Wall Street analysts forecast AMGN stock price to fall 4.0% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$390.94
-4.0% Upside
Previously C$389.22 on Sep 25, 2026
Current Price
C$407.27
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.1%
Annualized
90-Day Vol
33.0%
Annualized
Trend (90d)
+45.0%
Annualized drift
90d Mean
C$478.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$429.71 | C$374.24 – C$493.39 |
| 60 trading days | C$453.38 | C$372.89 – C$551.23 |
| 90 trading days | C$478.35 | C$376.53 – C$607.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Amgen's upcoming earnings report, as analysts expect slight growth in earnings and revenue. However, the recent stock performance raises concerns about the company's market positioning.
3.38%
Amgen's stock fell 3.38% yesterday, underperforming compared to the S&P 500's gain of 0.2%.
Bull case
Amgen's strong revenue base of CA$38.1 billion gives it advantages like economies of scale and negotiating power. If managed well, this could lead to future growth.
Bear case
The stock's recent performance, lagging behind the S&P 500 and the medical sector, suggests that investor confidence may be declining, especially as the company approaches its earnings disclosure.
Market Context
Advertisement
Amgen's stock fell 3.38% yesterday, contrasting sharply with the S&P 500's gain of 0.2%. This underperformance is concerning as the biotech sector faces increasing competition and scrutiny, with other companies making significant progress.
Earnings Outlook
As Amgen prepares for its upcoming earnings report, analysts project earnings per share of CA$5.69, indicating a modest increase. Revenue expectations stand at CA$9.91 billion, reflecting a 3.68% growth year-over-year. However, the recent stock decline raises questions about whether these projections will be met.
Investor Sentiment
The recent dip in Amgen's stock price has led to cautious sentiment among investors. With a Zacks Rank of #3 (Hold), the company's valuation metrics, including a forward P/E ratio of 18.38, suggest that while it may be undervalued compared to its peers, the market's confidence appears to be waning.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
